MANNKIND CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MANNKIND CORP (MNKD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $10.23M, a 35.98% increase year-over-year.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.46M, a 19.87% increase year-over-year.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.32M, a 17.39% decline year-over-year.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.52M, a 16.99% increase year-over-year.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $24.20M, a 13.28% increase from fiscal 2024.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $21.36M, a 21.02% increase from fiscal 2023.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $17.65M, a 31.25% increase from fiscal 2022.
- MANNKIND CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $13.45M, a 10.22% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.23M 10-Q · filed 2026-08-05 | $16.68M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $6.46M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $24.20M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $4.32M 10-Q · filed 2025-11-05 | $11.84M derived: sum of 2 quarters · filed 2026-08-05 | $17.22M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $7.52M 10-Q · filed 2026-08-05 | $12.90M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $5.38M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $21.36M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $5.23M 10-Q · filed 2025-11-05 | $11.65M derived: sum of 2 quarters · filed 2025-11-05 | $15.54M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $6.43M 10-Q · filed 2025-11-05 | $10.31M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $3.88M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $17.65M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $4.60M 10-Q · filed 2024-11-07 | $10.18M derived: sum of 2 quarters · filed 2024-11-07 | $13.84M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $5.58M 10-Q · filed 2024-11-07 | $9.23M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $3.65M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $13.45M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $3.62M 10-Q · filed 2023-11-07 | $8.04M derived: sum of 2 quarters · filed 2023-11-07 | $10.85M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $4.42M 10-Q · filed 2023-11-07 | $7.23M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $2.81M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $12.20M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $3.18M 10-Q · filed 2022-11-08 | $7.11M derived: sum of 2 quarters · filed 2022-11-08 | $9.04M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.93M 10-Q · filed 2022-11-08 | $5.86M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $1.94M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $6.51M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $1.29M 10-Q · filed 2021-11-09 | $3.48M derived: sum of 2 quarters · filed 2021-11-09 | $4.61M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $2.19M 10-Q · filed 2021-11-09 | $3.31M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $1.13M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $6.20M 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $1.64M 10-Q · filed 2020-11-04 | $4.21M derived: sum of 2 quarters · filed 2020-11-04 | $5.21M derived: sum of 3 quarters · filed 2020-11-04 | |
| 2019-06-30 | $2.57M 10-Q · filed 2020-11-04 | $3.57M derived: sum of 2 quarters · filed 2020-11-04 | ||
| 2019-03-31 | $999.00K 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $6.86M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $1.56M 10-Q · filed 2019-11-08 | $3.77M derived: sum of 2 quarters · filed 2019-11-08 | $5.71M derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $2.21M 10-Q · filed 2019-11-08 | $4.15M derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $1.94M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $4.85M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $5.13M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $8.72M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $25.66M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $45.19M 10-K · filed 2016-03-15 | |||
| 2012-12-31 | $13.29M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $11.20M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $13.58M 10-K · filed 2014-03-03 | |||
| 2009-12-31 | $20.22M 10-K · filed 2014-03-03 | |||
| 2008-12-31 | $24.81M 10-K · filed 2014-03-03 | |||
| 2007-12-31 | $17.52M 10-K · filed 2014-03-03 | |||
| 2006-12-31 | $14.67M 10-K · filed 2014-03-03 | |||
| 2005-12-31 | -$1.83M 10-K · filed 2014-03-03 | |||
| 2004-12-31 | $6.81M 10-K · filed 2014-03-03 | |||
| 2003-12-31 | $4.50M 10-K · filed 2014-03-03 | |||
| 2002-12-31 | $268.00K 10-K · filed 2014-03-03 | |||
| 2001-12-31 | $1.56M 10-K · filed 2014-03-03 | |||
| 2000-12-31 | $9.61M 10-K · filed 2014-03-03 | |||
| 1998-12-31 | $150.00K 10-K · filed 2014-03-03 | |||
| 1997-12-31 | $2.00K 10-K · filed 2014-03-03 | |||
| 1996-12-31 | $126.00K 10-K · filed 2014-03-03 | |||
| 1995-12-31 | $384.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |